Advertisement

VirusDisease

, Volume 27, Issue 1, pp 55–62 | Cite as

Analysis of mutations in the core and NS5A genes of hepatitis C virus in non-responder and relapser patients after treatment with Peg-IFN-α and ribavirin

  • Kattareeya Kumthip
  • Pattranuch Chusri
  • Chansom Pantip
  • Satawat Thongsawat
  • Amornrat O’Brien
  • Niwat ManeekarnEmail author
Original Article
  • 157 Downloads

Abstract

Mutations in several regions of HCV genome are shown to correlate with response to interferon (IFN) treatment. Persistence of HCV infection and poor susceptibility to treatment might be contributed by mutations arising within HCV genome which enable the virus to escape from host immune response/IFN treatment. This study investigated mutations in core and NS5A genes of HCV from non-responder and relapser patients after treatment with Peg-IFN-α and ribavirin. Viral RNA was extracted from patient sera and core and NS5A genes were amplified by RT-PCR. Nucleotide sequences of the core and NS5A genes were determined by direct sequencing, and converted to amino acid sequences. Nucleotide and amino acid sequences in the core region, ISDR, PKRBD, and V3 regions within NS5A after treatment were highly conserved when comparing to their corresponding sequences obtained before treatment. Interestingly, when comparing the virus from relapsers to those from non-responders, the number of mutations after treatment in N-terminal region of NS5A of virus from relapsers was significantly higher than those from non-responders (P < 0.05). Amino acid mutations at the N-terminus of NS5A of the virus in relapsers might help the virus to survive and somehow relapse after the cessation of the treatment.

Keywords

Core Hepatitis C virus Mutation NS5A Peg-IFN-α Ribavirin 

Notes

Acknowledgments

This study was supported by the Thailand Research Fund (TRF), the National Research Council of Thailand (NRCT), and the Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.

References

  1. 1.
    Akuta N, Suzuki F, Sezaki H, et al. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. Intervirology. 2005;48(6):372–80.CrossRefPubMedGoogle Scholar
  2. 2.
    Castillo I, Rodriguez-Inigo E, Bartolome J, et al. Hepatitis C virus replicates in peripheral blood mononuclear cells of patients with occult hepatitis C virus infection. Gut. 2005;54(5):682–5.PubMedCentralCrossRefPubMedGoogle Scholar
  3. 3.
    Cuevas JM, Torres-Puente M, Jimenez-Hernandez N, et al. Refined analysis of genetic variability parameters in hepatitis C virus and the ability to predict antiviral treatment response. J Viral Hepat. 2008;15(8):578–90.CrossRefPubMedGoogle Scholar
  4. 4.
    Enomoto N, Sakuma I, Asahina Y, et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med. 1996;334(2):77–81.CrossRefPubMedGoogle Scholar
  5. 5.
    Escudero A, Rodriguez F, Serra MA, Del Olmo JA, Montes F, Rodrigo JM. Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study. J Gastroenterol Hepatol. 2008;23(6):861–6.CrossRefPubMedGoogle Scholar
  6. 6.
    Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347(13):975–82.CrossRefPubMedGoogle Scholar
  7. 7.
    Gale MJ Jr, Korth MJ, Tang NM, et al. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology. 1997;230(2):217–27.CrossRefPubMedGoogle Scholar
  8. 8.
    Gale MJ Jr, Korth MJ, Katze MG. Repression of the PKR protein kinase by the hepatitis C virus NS5A protein: a potential mechanism of interferon resistance. Clin Diagn Virol. 1998;10(2–3):157–62.CrossRefPubMedGoogle Scholar
  9. 9.
    Gerotto M, Dal Pero F, Sullivan DG, et al. Evidence for sequence selection within the non-structural 5A gene of hepatitis C virus type 1b during unsuccessful treatment with interferon-alpha. J Viral Hepat. 1999;6(5):367–72.CrossRefPubMedGoogle Scholar
  10. 10.
    Gong GZ, Lai LY, Jiang YF, He Y, Su XS. HCV replication in PBMC and its influence on interferon therapy. World J Gastroenterol. 2003;9(2):291–4.PubMedCentralCrossRefPubMedGoogle Scholar
  11. 11.
    Hayashi K, Katano Y, Ishigami M, et al. Mutations in the core and NS5A region of hepatitis C virus genotype 1b and correlation with response to pegylated-interferon-alpha 2b and ribavirin combination therapy. J Viral Hepat. 2011;18(4):280–6.CrossRefPubMedGoogle Scholar
  12. 12.
    Hofmann WP, Zeuzem S, Sarrazin C. Hepatitis C virus-related resistance mechanisms to interferon alpha-based antiviral therapy. J Clin Virol. 2005;32(2):86–91.CrossRefPubMedGoogle Scholar
  13. 13.
    Januszkiewicz-Lewandowska D, Wysocki J, Pernak M, et al. Presence of hepatitis C virus (HCV)-RNA in peripheral blood mononuclear cells in HCV serum negative patients during interferon and ribavirin therapy. Jpn J Infect Dis. 2007;60(1):29–32.PubMedGoogle Scholar
  14. 14.
    Kumthip K, Pantip C, Chusri P, et al. Correlation between mutations in the core and NS5A genes of hepatitis C virus genotypes 1a, 1b, 3a, 3b, 6f and the response to pegylated interferon and ribavirin combination therapy. J Viral Hepat. 2011;18(4):e117–25.CrossRefPubMedGoogle Scholar
  15. 15.
    Kumthip K, Chusri P, Pantip C, et al. Hepatitis C virus genotypes circulating in patients with chronic hepatitis C in Thailand and their responses to combined PEG-IFN and RBV therapy. J Med Virol. 2014;86(8):1360–5.CrossRefPubMedGoogle Scholar
  16. 16.
    Marrone A, Sallie R. Genetic heterogeneity of hepatitis C virus. The clinical significance of genotypes and quasispecies behavior. Clin Lab Med. 1996;16(2):429–49.PubMedGoogle Scholar
  17. 17.
    Martell M, Esteban JI, Quer J, et al. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J Virol. 1992;66(5):3225–9.PubMedCentralPubMedGoogle Scholar
  18. 18.
    Munoz de Rueda P, Casado J, Paton R, et al. Mutations in E2-PePHD, NS5A-PKRBD, NS5A-ISDR, and NS5A-V3 of hepatitis C virus genotype 1 and their relationships to pegylated interferon-ribavirin treatment responses. J Virol. 2008;82(13):6644–53.CrossRefPubMedGoogle Scholar
  19. 19.
    Nousbaum J, Polyak SJ, Ray SC, et al. Prospective characterization of full-length hepatitis C virus NS5A quasispecies during induction and combination antiviral therapy. J Virol. 2000;74(19):9028–38.PubMedCentralCrossRefPubMedGoogle Scholar
  20. 20.
    Okanoue T, Itoh Y, Hashimoto H, et al. Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study. J Gastroenterol. 2009;44(9):952–63.CrossRefPubMedGoogle Scholar
  21. 21.
    Pawlotsky JM, Germanidis G, Neumann AU, Pellerin M, Frainais PO, Dhumeaux D. Interferon resistance of hepatitis C virus genotype 1b: relationship to nonstructural 5A gene quasispecies mutations. J Virol. 1998;2(4):2795–805.Google Scholar
  22. 22.
    Reed KE, Rice CM. Overview of hepatitis C virus genome structure, polyprotein processing, and protein properties. Curr Top Microbiol Immunol. 2000;242:55–84.PubMedGoogle Scholar
  23. 23.
    Tai AW, Chung RT. Treatment failure in hepatitis C: mechanisms of non-response. J Hepatol. 2009;50(2):412–20.PubMedCentralCrossRefPubMedGoogle Scholar
  24. 24.
    Taliani G, Badolato C, Lecce R, et al. Hepatitis C virus RNA in peripheral blood mononuclear cells: relation with response to interferon treatment. J Med Virol. 1995;47(1):16–22.CrossRefPubMedGoogle Scholar
  25. 25.
    Tellinghuisen TL, Marcotrigiano J, Rice CM. Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase. Nature. 2005;435(7040):374–9.PubMedCentralCrossRefPubMedGoogle Scholar
  26. 26.
    Tellinghuisen TL, Foss KL, Treadaway J. Regulation of hepatitis C virion production via phosphorylation of the NS5A protein. PLoS Pathog. 2008;4(3):e1000032.PubMedCentralCrossRefPubMedGoogle Scholar
  27. 27.
    Tong CY, Gilmore IT, Hart CA. HCV-associated liver cancer. Lancet. 1995;345(8956):1058–9.CrossRefPubMedGoogle Scholar
  28. 28.
    Torres-Puente M, Cuevas JM, Jimenez-Hernandez N, et al. Genetic variability in hepatitis C virus and its role in antiviral treatment response. J Viral Hepat. 2008;15(3):188–99.CrossRefPubMedGoogle Scholar
  29. 29.
    Wang JT, Sheu JC, Lin JT, Wang TH, Chen DS. Detection of replicative form of hepatitis C virus RNA in peripheral blood mononuclear cells. J Infect Dis. 1992;166(5):1167–9.CrossRefPubMedGoogle Scholar
  30. 30.
    Wohnsland A, Hofmann WP, Sarrazin C. Viral determinants of resistance to treatment in patients with hepatitis C. Clin Microbiol Rev. 2007;20(1):23–38.PubMedCentralCrossRefPubMedGoogle Scholar

Copyright information

© Indian Virological Society 2016

Authors and Affiliations

  • Kattareeya Kumthip
    • 1
  • Pattranuch Chusri
    • 1
  • Chansom Pantip
    • 2
  • Satawat Thongsawat
    • 3
  • Amornrat O’Brien
    • 1
  • Niwat Maneekarn
    • 1
    Email author
  1. 1.Department of Microbiology, Faculty of MedicineChiang Mai UniversityChiang MaiThailand
  2. 2.Research Institute for Health SciencesChiang Mai UniversityChiang MaiThailand
  3. 3.Department of Internal Medicine, Faculty of MedicineChiang Mai UniversityChiang MaiThailand

Personalised recommendations